AMLX
Amylyx Pharmaceuticals IncNASDAQ
Healthcare • Drug Manufacturers - Specialty & Generic
Factor tilt: Mid-Cap Blend
$29.50+6.81%
Close Nov 6, 2026
- Market cap
- $3.28B
- 1 month
- +8.5%
- 3 months
- +30.1%
- 1 year
- +122.8%
- 52-week range
- $11.38$39.66
- Dividend
- No dividends on record
- EPS estimate, results pending
- -$0.37Quarter ended Sep 30, 2026 · 8 analysts · revenue $41.6K · +0.9% in 30d
- Short interest
- 13.6% of float13.2M shares · settled Oct 15, 2026 · +4.6% since Sep 30, 2026 · FINRA
Estimate history · same fiscal quarter
Quarter ended Sep 30, 2026. Source: EODHD earnings_trend.
| Observed / analysts | EPS | Revenue |
|---|---|---|
| 8 analysts | -0.3718 | 41.6K |
| 8 analysts | -0.3718 | 41.6K |
| 8 analysts | -0.3718 | 41.6K |
| 8 analysts | -0.375 | 37.82K |
| 8 analysts | -0.375 | 37.82K |
Dates identify stored observations, not earnings announcements. Gaps do not mean estimates were unchanged. The analyst group and vendor earnings basis may change.
If you hold AMLX, compare changes in earnings expectations with your investment case. These are analyst estimates, not reported results or a prediction of your return.
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$152.09M
- Free cash flow
- -$126.72M
- Book value
- $239.17M
- Total debt
- $5.26M
- P/E
- —
- Price / sales
- —
- Price / book
- 13.7×
- FCF yield
- -3.9%
- Net margin
- —
EODHD (TTM) · as of Nov 8, 2026
End-of-day close from stored market data, not a live quote.
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Read more
It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Website
- amylyx.com
- Headquarters
- Cambridge, MA, United States
- Employees
- 136
- Listed
- Jan 7, 2022
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 25, 2026.
Quarterly results
The last 8 fiscal quarters from EODHD’s latest stored vendor-normalized figures. These may include restatements. Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | — | — | — | -$45.7M | -$43.4M |
| Mar 2026filed May 7, 2026 | — | — | — | -$43.8M | -$41.3M |
| Dec 2025filed Mar 3, 2026 | — | — | — | -$36.6M | -$33.0M |
| Sep 2025filed Nov 6, 2025 | — | — | — | -$36.0M | -$34.4M |
| Jun 2025filed Aug 7, 2025 | — | — | — | -$42.9M | -$41.4M |
| Mar 2025filed May 8, 2025 | — | — | — | -$37.8M | -$35.9M |
| Dec 2024filed Mar 4, 2025 | — | — | — | -$40.7M | -$37.5M |
| Sep 2024filed Nov 7, 2024 | $416.0K | -99.6% | -94.5% | -$75.7M | -$72.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 3, 2026 | — | — | — | -$153.3M | -$144.7M |
| Dec 2024filed Mar 4, 2025 | $87.4M | — | 51.8% | -$314.7M | -$301.7M |
| Dec 2023filed Feb 22, 2024 | — | — | — | — | — |
| Dec 2022filed Mar 13, 2023 | $22.2M | +7,700.0% | 86.5% | -$201.3M | -$198.4M |
| Dec 2021filed Mar 31, 2022 | $285.0K | -56.2% | — | -$82.7M | -$87.9M |
| Dec 2020filed Dec 31, 2020 | $650.0K | -54.4% | -3,683.7% | -$39.0M | -$42.3M |
Annual cash generation
Does profit turn into cash? Compare AMLX’s accounting profit with operating cash flow and capital spending. Amounts are in USD.
Fiscal year ending
- Net income
- -$144.7M
- Operating cash flow
- -$123.3M
- Capital spending
- $138.0K
- Free cash flow
- -$123.5M
Fiscal year ending
- Net income
- -$301.7M
- Operating cash flow
- -$167.6M
- Capital spending
- $157.0K
- Free cash flow
- -$167.8M
Fiscal year ending
- Net income
- Unavailable
- Operating cash flow
- $11.9M
- Capital spending
- $1.2M
- Free cash flow
- $10.7M
Earlier cash-flow years
Fiscal year ending
- Net income
- -$198.4M
- Operating cash flow
- -$179.9M
- Capital spending
- $2.5M
- Free cash flow
- -$182.4M
Fiscal year ending
- Net income
- -$87.9M
- Operating cash flow
- -$74.8M
- Capital spending
- $353.0K
- Free cash flow
- -$75.2M
Fiscal year ending
- Net income
- -$42.3M
- Operating cash flow
- -$36.7M
- Capital spending
- $151.0K
- Free cash flow
- -$36.8M
If you hold or are researching AMLX, compare cash generation and investment needs with your thesis. Working capital and non-cash charges can separate profit from cash. Capital spending can reduce free cash flow while earnings rise. For a long or short position, that gap alone does not predict a price move.
Cash-flow source and meaning
Source: EODHD annual financial statements, latest stored vendor-normalized figures. These may include restatements and may differ from the filer’s own XBRL. A filing date is not the knowledge date of this version of the values.
Free cash flow is the vendor’s reported figure, shown only when it agrees with operating cash flow less capital spending recorded as a positive outflow. It is not cash guaranteed for dividends or buybacks, and it does not subtract every financing obligation. Missing or sign-incompatible inputs are not filled in. An unlabelled currency is used only for a confirmed domestic USD filer. These are annual statements, not forecasts or an originally-filed history.
Company Quality Grade
How steadily did the business compound its per-share book value with dividends over 40 quarters? This historical measure is not a stock-price return or a forecast.
As of
Grade withheld by the published method. This is not a zero or a poor-quality verdict.
- There is not enough continuous first-filed history for this window.
insufficient_history
If you hold AMLX, use this to question the durability of the business behind your investment case, alongside its filings and valuation. A withheld grade is a data or method limit, not a sell signal. For a short position, it does not predict timing, borrowing costs or downside. It does not measure your account’s return.
Method, filing sources and publication receipt
Source: SEC first-filed XBRL. Midas Edge API’s published Green Compounders method uses only filings public by the as-of date, split-adjusted shares and the original filed values. Restatements do not replace them. Issuer pools and entity types reflect the SEC submissions captured for this run, not historical classifications at each as-of date.
The primary form fits log book value with reinvested dividends against time. The method checks the starting book and market-cap floors and excludes identified non-reliance/enforcement windows. Its cohort is fixed at capture time, so historical percentiles have capture and survival limits. It does not check audit-opinion going-concern text. This grade is separate from InsiderIQ, HolderIQ and NetCredibility.
- Parameters
- pg-g2-params.v17
- Plane
- sha256:841c1bb46826c45b96472bf9adff6a93c8ce5f5392636cff297045298e9bf517
- Grade row SHA-256
- sha256:6f35db8871e8af3d40f17b97acfcc388e9dbb8fe1340d07368f33ab81df875ec
- Manifest SHA-256
- sha256:c94c0931ffa7d9818ad0d34110b400f347a53da8a9c7d9aee1013095384d6a8a
- Engine SHA-256
- sha256:defa2e17f100b92a30576940d1632532b5cc4f37a2cb4bcc7fcc881856417811
- Hand-check receipt SHA-256
- sha256:03dd742b7b83e1130b4c01f9beaaf2671b20562c447a337dd047a41ad675ed3c
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched AMLX. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
13,249,442 shares short
+582,471 shares (+4.6%) vs Sep 30, 2026
13.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
12,666,971 shares short
-845,782 shares (-6.3%) vs Sep 15, 2026
13% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
13,512,753 shares short
+775,552 shares (+6.1%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
12,737,201 shares short
-687,905 shares (-5.1%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
13,425,106 shares short
+23,384 shares (+0.2%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
13,401,722 shares short
+1,135,729 shares (+9.3%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind AMLX’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 9, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if AMLX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
47 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 33 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
207 filers reported a long position in AMLX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
57.4%
of the 115M shares 13-F filers reported
Moves vs Q1 2026
6 added1 trimmed
2 unchanged · 1 not comparable
Net shares held
+2.5%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $300.4M · 16.7M shares | 16.7M | +0.6% |
| 2 | BlackRock, Inc. | $158.5M · 8.8M shares | 8.8M | 0% |
| 3 | Perceptive Advisors LLC | $149.7M · 8.3M shares | 8.3M | +0.6% |
| 4 | TCG Crossover Management, LLC | $112.1M · 6.2M shares | 6.2M | Unchanged |
| 5 | Commodore Capital LP | $101.5M · 5.7M shares | 5.7M | Unchanged |
| 6 | Jupiter Topco LLC | $94M · 5.2M shares | 5.2M | — |
| 7 | Saturn V Capital Management LP | $83M · 4.6M shares | 4.6M | +6.3% |
| 8 | Vanguard Capital Management LLC | $75.9M · 4.2M shares | 4.2M | +2% |
| 9 | Morgan Stanley | $56.2M · 3.1M shares | 3.1M | +43.9% |
| 10 | Driehaus Capital Management LLC | $54.5M · 3M shares | 3M | +1.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of AMLX file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| May 15, 2026 | Perceptive Advisors LLC13G · passive · amended | 7.5% |
| Mar 26, 2026 | Vanguard Group Inc13G · passive · amended | 0%under 5% |
Get the Full Analysis for AMLX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.